Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmaKodex Ltd.

This article was originally published in Start Up

Executive Summary

PharmaKodex, a joint venture of Vectura Group and Unilever Ventures, is developing oral and dermal delivery systems that improve availability, thus improving drug response time and activity, leading to greater patient acceptance. The company is adding a twist to the standard low-risk reformulation model now ubiquitous in the specialty pharma world; it intends to use its technologies to develop OTC drugs that will hit market faster and bring in revenue to fund prescription drug development.
Advertisement

Related Content

Macromolecules & Spec Pharma: The Good News in Drug Delivery
Start-Up Previews (4/07)
Macromolecules & Spec Pharma: The Good News in Drug Delivery
Drug Delivery in a Product-Oriented World
Drug Delivery: Moving from Platform to Product

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel